- Home
- FOXO vs CERO Comparison
FOXO vs CERO Comparison
Compare FOXO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXO
- CERO
- Stock Information
- Founded
- FOXO 2019
- CERO 2017
- Country
- FOXO United States
- CERO United States
- Employees
- FOXO N/A
- CERO N/A
- Industry
- FOXO Retail: Computer Software & Peripheral Equipment
- CERO
- Sector
- FOXO Technology
- CERO
- Exchange
- FOXO Nasdaq
- CERO Nasdaq
- Market Cap
- FOXO 4.9M
- CERO 8.4M
- IPO Year
- FOXO N/A
- CERO N/A
- Fundamental
- Price
- FOXO $0.24
- CERO $2.06
- Analyst Decision
- FOXO
- CERO
- Analyst Count
- FOXO 0
- CERO 0
- Target Price
- FOXO N/A
- CERO N/A
- AVG Volume (30 Days)
- FOXO 9.1M
- CERO 737.7K
- Earning Date
- FOXO 11-19-2024
- CERO 02-24-2025
- Dividend Yield
- FOXO N/A
- CERO N/A
- EPS Growth
- FOXO N/A
- CERO N/A
- EPS
- FOXO N/A
- CERO N/A
- Revenue
- FOXO $1,341,000.00
- CERO N/A
- Revenue This Year
- FOXO N/A
- CERO N/A
- Revenue Next Year
- FOXO N/A
- CERO N/A
- P/E Ratio
- FOXO N/A
- CERO N/A
- Revenue Growth
- FOXO 196.03
- CERO N/A
- 52 Week Low
- FOXO $0.13
- CERO $1.70
- 52 Week High
- FOXO $1.30
- CERO $1,095.00
- Technical
- Relative Strength Index (RSI)
- FOXO 46.29
- CERO 37.15
- Support Level
- FOXO $0.20
- CERO $1.70
- Resistance Level
- FOXO $0.23
- CERO $2.22
- Average True Range (ATR)
- FOXO 0.02
- CERO 0.30
- MACD
- FOXO 0.00
- CERO 0.27
- Stochastic Oscillator
- FOXO 52.70
- CERO 24.32
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.